Skip to main content
Expand main menu
Close main menu
WBA makes $970M majority investment in Shields Health Solutions
Walgreens Boots Alliance hopes to use the investment in the specialty pharmacy company as a means of speeding up the development of new healthcare models and creating a platform from which to build partnerships with health systems.
Hikma, FAES Farma ink licensing agreement for Bilastine
Hikma will be responsible for commercializing Bilastine once it is FDA approved.
Amber Specialty Pharmacy, Hy-Vee Pharmacy Solutions to administer Regeneron monoclonal antibody treatment
Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions have 21 locations in the United States and Puerto Rico that are licensed to administer Regeneron’s monoclonal antibody treatment.
Amber Specialty Pharmacy to dispense Kadmon’s Rezurock
Amber Specialty Pharmacy will support oncology and bone marrow transplant providers and patients throughout the country.
ParaPRO intros Natroba
ParaPro's Natroba is the first product for scabies to be approved by the Food and Drug Administration in more than 30 years.
Optum Frontier Therapies debuts in Las Vegas
Optum Frontier Therapies' flagship location will serve rare disease patients in all 50 states.
Sun Pharma, Cassiopea ink license, supply agreements for Winlevi
Sun Pharma will have the exclusive right to commercialize Winlevi in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.
AllianceRx Walgreens Prime earns URAC reaccreditation for home delivery pharmacy
URAC’s full accreditation status means AllianceRx Walgreens Prime’s home delivery services are meeting industry-leading standards.
AllianceRx Walgreens Prime highlights financial assistance efforts
The company said it has connected eligible patients to more than $600 million in financial assistance in the past two years.
Zydus Cadila receives tentative FDA OK for generic Tagrisso
Zydus Cadila's osimertinib provides a generic treatment for lung cancer.
Foresee Pharmaceuticals receives FDA nod for Camcevi
Camcevi 42 mg subcutaneous injection is a gonadotropin-releasing hormone agonist indicated for the treatment of adult patients with advanced prostate cancer.
AllianceRx Walgreens Prime offering hard-to-find HIV medicines
The first once-monthly injectable, and oral anti-diarrheal are accessible for adults living with HIV-1.
Amber Specialty Pharmacy partners with MarkeTouch Media to enhance care coordination
With MarkeTouch Media’s TouchPoint Management solution, Amber Specialty Pharmacy saw improvements in patient adherence, patient experience, and overall satisfaction.
Amneal acquires Kashiv Specialty Pharmaceuticals
Through the acquisition of Kashiv Specialty Pharmaceuticals, Amneal has gained a pipeline of 505(b)2 branded products and complex generics.